Rinvoq® (upadacitinib) – New indication
On December 14, 2021, AbbVie announced the FDA approval of Rinvoq (upadacitinib), for the treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.
Download PDF
